MedPath

Effect of Marma Chikitsa on Vatashthila (Benign Prostate Hyperplaisa)

Not yet recruiting
Conditions
Benign prostatic hyperplasia withlower urinary tract symptoms. Ayurveda Condition: VATASHTHILA, (2) ICD-10 Condition: N33||Bladder disorders in diseases classified elsewhere. Ayurveda Condition: VATASHTHILA (Benign Prostate Hyperplasia),
Registration Number
CTRI/2023/03/051080
Lead Sponsor
Pandit Khushilal Sharma Government Autonomous Ayurveda College and Institute Bhopal MP
Brief Summary

IN THIS STUDY DETAILS OF MUTRAGHAT WITH SPECIAL REFRENCE TO VATASHTHILA  AND THE MODERN REFERENCE OF BENIGN PROSTATE HYPERPLASIA WILL BE DONE FROM LITERATURE.

WE WILL EVALUATE THE EFFECT OF MARMA CHIKITSA IN THE MANAGEMENT OF MUTRAGHAT WITH SPECIAL REFRENCE TO VATASHTHILA (BPH).

The initial assessment included the

**International Prostatic Symptoms Score (IPSS)**

The International Prostate Symptom Score (I-PSS) is based on the answers to seven

Questions concerning urinary symptoms.. Each question concerning urinary symptoms

allows the patient to choose one out of six answers indicating increasing severity of the

Particular symptom. The answers are assigned points from 0 to 5.

Thetotal score can therefore range from 0 to 35 (asymptomatic to very symptomatic).The questions refer to the following urinary symptoms: Questions included in I-PSS score..

 1      Incomplete emptying  2 Frequency 3 Intermittency 4 Urgency5 Weak Stream

6 Straining7 Nocturia

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Male
Target Recruitment
30
Inclusion Criteria
  • 1.The Patients with IPSS International prostatic Symptom Score (0-7) Mild and ( 8-19 )Moderate.
  • 2.Patient willing to be registered for study with written consent.
  • 3.Patient having BMI less than 30 kg/m2.
Exclusion Criteria
  • 1.Patients below the age of 45 years and above 85 years.
  • 2.Patient having BMI more than 30kg/m2.
  • 3Patient with IPSS International Prostatic Symptom score (19-35)Severe.
  • 4Patient with any severe illness Like Tuberculosis, Cardiac Disease ,Liver disease or Any Malignancy.
  • 5.Patient having severe psychiatric illness.
  • 6.Patients not willing for written consent.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
It is expected that at the end of study, scholar will be able to evaluate Effect of Marma Chikitsa in the Management of Mutraghat with special reference to Vatashthila (Benign Prostate Hyperplasia)1Incomplete emptying 2 Frequency 3 Intermittency 4 Urgency5 Weak StreamIt is expected that at the end of 3 months, scholar will be able to evaluate Effect of Marma Chikitsa in the Management of Mutraghat with special reference to Vatashthila (Benign Prostate Hyperplasia)1Incomplete emptying 2 Frequency 3 Intermittency 4 Urgency5 Weak Stream | 6 Straining7 Nocturia
6 Straining7 NocturiaIt is expected that at the end of 3 months, scholar will be able to evaluate Effect of Marma Chikitsa in the Management of Mutraghat with special reference to Vatashthila (Benign Prostate Hyperplasia)1Incomplete emptying 2 Frequency 3 Intermittency 4 Urgency5 Weak Stream | 6 Straining7 Nocturia
Secondary Outcome Measures
NameTimeMethod
It is expected that at the end of study, scholar will be able to evaluate Effect of Marma Chikitsa in the Management of Mutraghat with special reference to Vatashthila (Benign Prostate Hyperplasia)It is expected that at the end of 3 months, scholar will be able to evaluate Effect of Marma Chikitsa in the Management of Mutraghat with special reference to Vatashthila (Benign Prostate Hyperplasia)

Trial Locations

Locations (1)

Pandit Khushilal Sharma Government Autonomous College and Institute Bhopal MP

🇮🇳

Bhopal, MADHYA PRADESH, India

Pandit Khushilal Sharma Government Autonomous College and Institute Bhopal MP
🇮🇳Bhopal, MADHYA PRADESH, India
Dr Ashwarya Vijayvargiya
Principal investigator
9981306425
aishwaryavijaywargiya65@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.